Articles tagged with Cell Therapies
Researchers found that rituximab, a monoclonal antibody, was safe and effective in reducing liver damage in PBC patients who had an incomplete response to UDCA therapy. The study showed significant reductions in alkaline phosphatase levels and anti-mitochondrial antibodies after treatment.
Researchers studied the role of immune responses in oncolytic adenovirus therapy and found that CD8+ T cells mediate antitumor efficacy. The study proposes a new therapeutic regime combining oncolytic adenovirus with immunotherapy.
Researchers at UCLA have identified dihydromyricetin as a potential treatment for acute alcohol intoxication and withdrawal symptoms. The compound blocks the action of alcohol on the brain's GABAA receptors, reducing voluntary consumption without major side effects.
A study of over 26,000 patients found that therapeutic hypothermia was used in only 0.35% of out-of-hospital cardiac arrest cases in the US. Despite its proven benefits in reducing mortality and improving neurologic outcomes after a heart attack, hypothermic therapy is not being widely adopted in clinical practice.
Researchers at the Weizmann Institute have developed a new form of adoptive cell transfer that overcomes limitations of current therapies. This approach uses a donor pool of immune T cells prepared in advance, which are outfitted with receptors to specifically target and destroy tumors.
Researchers have identified a distinct population of immune cells that contribute to the pathogenesis of type 1 diabetes by helping CD8+ T cells elicit autoimmune responses in the pancreas. This subset of CD4+ T cells produces IL-21 and express CCR9, playing a critical role in autoimmune disease.
University of Cincinnati researchers have successfully produced large RNA nanoparticles using a bipartite approach, overcoming challenges in industry-scale production. The nanoparticles, containing small interfering RNA, show a half-life of between five and 10 hours in animal models, are non-toxic and produce no immune response.
For patients with confirmed high-grade dysplasia, endoscopic eradication therapy is recommended. Surveillance may be considered in some cases, but it is not a substitute for treatment. The American Gastroenterological Association recommends regular screening for cardiovascular risk factors and interventions.
Researchers have developed a cell therapy that selectively dampens vascular inflammation induced by LDL, showing substantial protective effects against atherosclerosis. The treatment has been shown to reduce the disease process by up to 70 percent in mouse studies.
Researchers discovered that activated T cells play a key role in IRIS, producing excessive interferon gamma and triggering an exaggerated immune response. A new animal model also confirmed the involvement of macrophages in sparking IRIS. These findings may lead to targeted prevention or therapy for HIV patients developing IRIS.
Scientists have developed a novel method to deliver therapeutic molecules, proteins, and DNA directly into living cells using laser-activated nanoparticles. The technique, which uses bursts of near-infrared light to create tiny holes in cell membranes, shows promise for gene-based therapies.
Researchers at Medical College of Georgia have identified a rare hybrid cell that can switch the immune system on or off, expressing indoleamine 2,3 dioxygenase to turn off T cells. This unique cell has properties of both dendritic and B cells, with potential implications for cancer and rheumatoid arthritis therapies.
Researchers have identified eIF5A as a crucial player in pancreatic beta cell dysfunction in diabetes. Blocking hypusine modification of eIF5A protected mice in a model of diabetes, suggesting potential therapeutics for preserving beta cell function.
Researchers have found that regulatory T cells slow down the immune response too soon, limiting vaccine effectiveness. By removing these cells, they discovered a two-fold increase in immune response to HIV vaccine.
Researchers at LSU Health Sciences Center have identified a novel mechanism that triggers brain damage during stroke, which they believe can be blocked using a high-potency reagent. This breakthrough may provide a new therapeutic target for stroke therapy, offering hope for patients affected by this devastating disease.
A new technique uses microscopic magnetic particles to target stem cells to sites of cardiovascular injury, resulting in a five-fold increase in cell localization and six-fold increase in cell capture. The method is directly applicable to clinical practice and could lead to the treatment of heart attacks and other vascular injuries usi...
Scientists discover a single transcription factor that can convert alpha cells into functional beta cells, increasing their number eight-fold in mice. The study shows promise for a potential new treatment for type I diabetes, where the body autodestructs beta cells leading to insulin deficiency and complications.
Researchers discovered a protein profile that may accurately predict tamoxifen resistance in breast cancer patients. The study found that the extracellular matrix metalloproteinase inducer (EMMPRIN) was significantly associated with an earlier tumor progression and poor clinical outcome.
A new study found that intermittent IL-7 therapy, combined with conventional antiretroviral therapy (c-ART), boosts the number of CD4+ and CD8+ T cells in HIV-infected patients with low T cell counts. This effect was observed for 48 weeks, suggesting a potential treatment option for these individuals.
A new study reveals that long-term non-progressors' immune cells can effectively contain HIV by stockpiling molecular weapons, enabling them to kill infected cells efficiently. The discovery advances understanding of the unique mechanisms behind this phenomenon and may inform the development of an HIV vaccine.
A phase II trial of Cybor-D, a combination therapy including cyclophosphamide, bortezomib, and dexamethasone, showed an improved response rate compared to traditional lenalidomide-dexamethasone therapy. The treatment resulted in a rapid initial decline and percentage reduction in M protein levels.
Two new studies provide insight into the molecular mechanisms underlying aberrant NF-κB activity in MM tumor cells. The research reveals diverse mutations that lead to pathological activation of NF-κB signaling in MM, highlighting its role as a target for therapy development.
Pazopanib, an oral angiogenesis inhibitor, demonstrated a 27% week 12 response rate and 73% total disease control rate in patients with advanced renal cell carcinoma. The study showed clear clinical activity in treating this type of cancer.
A team of students has invented a protective pouch that could improve cell therapy for diabetes patients. The pouch, made from nylon mesh and metal stents, holds microcapsules containing therapeutic cells, allowing them to thrive and produce insulin in the body.
A team of researchers from biology, chemistry, and engineering have developed a proposal for artificially created cells to treat diseases without injecting drugs. The cells would target and deliver chemicals needed by the body to function properly.
Researchers identified PTEN as a key regulator of Treg responsiveness to IL-2, enabling their proliferation and maintaining suppressive function. This discovery could provide a way to overcome the major challenge of harnessing Tregs for autoimmune disease treatment.
A new technology developed by Pall Corporation enables faster and more efficient cell harvesting for cell therapy, with processing times reduced to under 15 minutes. The system exhibits higher yield of cells and is easy to use, adhering to Good Manufacturing Practice (cGMP) regulations.
Neural transplants have provided long-term clinical benefits to three patients with Huntington's disease, improving motor and cognitive function. The procedure also led to focal improvements in brain metabolic activity, while secondary clinical alterations were observed due to the ongoing disease process.
Researchers at Johns Hopkins University developed tiny self-assembling cube-shaped containers that can deliver medications and cells. The cubes are trackable via MRI and have shown promising results in lab tests, including the release of microbeads and live cells.
Researchers have developed RNA nanoparticles that can carry multiple therapeutic agents into specific cancer cells, where they can halt viral growth or cancer progression. The tiny particles are assembled from three short pieces of ribonucleic acid and possess the right size and structure to gain entry into cells.
Researchers found that intermittent IL-2 administration induces high CD4 and CD8 cell proliferation followed by prolonged CD4 cell survival. This effect helps explain the preferential increase of CD4 cells in patients treated with IL-2 therapy.
Researchers identify optimal T cell selection and preparation strategies for adoptive immunotherapy approaches to treat tumors. Naive and early effector T cells are more effective than differentiated T cells in causing regression of large, established melanomas.
Researchers at UCSD found that statins and cholesterol depletors can reduce intracellular calcium levels and inhibit cell growth in pulmonary artery smooth muscle cells, which contributes to idiopathic pulmonary hypertension. This novel mechanism may provide a new approach for treating IPAH with current and future therapies.
New data from the largest study on CML patients (1106) showed improved rates of progression-free survival and durable responses to imatinib. Patients with early cytogenetic responses achieved higher progression-free survival rates, with 93% at 42 months compared to 74% without
Researchers found that adherence to St-Gallen guidelines improved overall survival at 7 years, especially for those at moderate risk of recurrence. Women whose treatment conformed to guideline recommendations experienced better survival and lower recurrence rates compared to those with non-guideline therapy.
Researchers developed a new technique to selectively delete C-fiber neurons, which transmit chronic pain signals, using the drug resiniferatoxin. In animal studies, this approach reduced pain and improved behavior without side effects.
The Russell Berrie Foundation gift will support cellular therapy research at Columbia University Irving Medical Center, aiming to restore body tissues and cure or ameliorate diabetes. The program seeks to engineer cells to produce insulin, potentially sparing patients from daily injections and devastating complications.
Researchers demonstrate that Ebola and Marburg viruses rely on lipid rafts in the cell membrane to gain entry and assemble. This finding opens up potential therapeutic avenues against these deadly pathogens.
Scientists at Uppsala University have identified a gene that regulates mast cell survival upon allergic activation, providing hope for a novel therapy to treat allergies. Inhibition of this gene, A1, leads to the death of mast cells, decreasing their numbers and alleviating allergic symptoms.
Researchers develop new therapies targeting related virus proteins, aiming to neutralize the effects of smallpox. The US population is highly susceptible due to low vaccination rates and limited vaccine stockpiles.
Researchers found that up to 96% of Parkinson's patients experience serious sleep disturbances, often overlooked by doctors. A new study suggests that cabergoline, a long-acting dopamine agonist, offers significant benefits in improving symptoms of sleep disturbance and daytime sleepiness.
A new radiation treatment technique targets head and neck tumors while sparing salivary glands, enabling patients to function more normally. Patients who received intensity-modulated radiation therapy (IMRT) experienced improved saliva flow and quality of life compared to conventional radiation therapies.
Two MS clinical trials halted due to adverse effects confirm the targeted peptide plays a role in the disease. The studies suggest that lower doses are better than higher doses, and immunological tests can determine how targeted therapies work in patients.
Researchers found that early antiviral treatment primes the immune system to suppress viral levels without drugs, achieving temporary suppression in several months. Five patients remained off treatment for up to 11 months, maintaining low viral levels.
A UF pilot study shows that massage and relaxation techniques can safely and effectively reduce pain, tension, and fatigue in patients with sickle cell anemia. The treatments improved blood flow and reduced muscle tension, providing relief from debilitating episodes of severe pain.
Researchers are developing BioMEMs, implant materials and devices that integrate micro- and nanoscale features to affect cellular function. These therapeutic systems use chip technology, material science, and bioengineering to grow heart cells in culture and protect implanted cells with precision.
Researchers found that even after six months of antiretroviral therapy, a substantial percentage of men with HIV remain infectious. The study suggests that men should continue to practice safe sex and follow medication instructions carefully.
A recent San Francisco study found that antiretroviral treatment continues to significantly improve AIDS patient survival rates, with a 60% reduction in risk of death for those receiving HAART. The study also revealed increased survival benefits over time, particularly among those diagnosed between 1996 and 1997.
Two studies compare the efficacy and adherence of the triple nucleoside regimen of Ziagen/Combivir versus PI-containing regimens. Preliminary data show that patients on the Ziagen/Combivir regimen had better viral load suppression, with 68% achieving <400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen.
Researchers found that adding interleukin-2 to highly active antiretroviral therapy improves CD4 cell counts in recently infected patients. After 48 weeks of treatment, the average CD4 cell count increased significantly in the early IL-2 group compared to the deferred group.
A multi-institutional study found that adding interleukin-2 to antiretroviral therapy increases CD4 cell counts and decreases detectable virus levels in HIV-infected patients. The study showed significant improvements in immunologic function, with 67% of patients achieving low viral loads.
Researchers at NIAID explore a new approach to HIV treatment involving cyclic therapy, which may reduce HAART duration and costs. Preliminary findings suggest that patients can maintain minimal viral loads and adequate CD4+ T cells during intermittent therapy.
Researchers found that adding IL-2 to antiretroviral therapy significantly increases CD4+ T-cell counts in HIV-infected patients. The study's results suggest that IL-2 may be used as a means of maintaining quality of life and decreasing AIDS-defining events.
Researchers at Duke University Medical Center have successfully used a heat-sensitive gene to slow down tumor growth in mice by 300-400 times over baseline. The gene therapy, which uses hyperthermia, also boosts the immune system's ability to fight cancer.
Researchers at Johns Hopkins presented Phase I study results for Taxoprexin DHA-paclitaxel, a novel taxane that tolerates high doses with minimal side effects. The drug delivers more therapeutic agent to tumor cells and less to healthy tissues, improving safety and effectiveness.
Researchers developed an intensive treatment combining radiation and chemotherapy to control locally advanced head and neck cancer, achieving complete local control for 92% of patients. The therapy increased long-term survival to 55%, with most side effects resolving after treatment.
A study of 947 HIV-positive individuals found that hospital admission was linked to unemployment (82%) and poor health status (46%). The study also showed that having a physician experienced in HIV/AIDS management was beneficial for avoiding hospital admissions.
The new guidelines take into account the availability of new anti-retroviral drugs and expanded therapy choices. Recommendations include initiating therapy based on viral load and CD4 cell count, choosing individualized regimens, and monitoring treatment response with CD4 and HIV RNA levels.
The new guidelines take into account the availability of new antiretroviral drugs and expanded therapy choices, recommending individualized treatment plans with a focus on convenience and adherence. Most patients with HIV infection can now live fully active lives with carefully monitored therapy and regimen changes.
A study by American Academy of Neurology finds that 'chasing the dragon' heroin use can produce a progressive brain disorder leading to permanent damage and death. Antioxidant therapy shows promise in treating the condition, but its effectiveness is uncertain.